4.7 Article

Simultaneous Testing for 6 Lysosomal Storage Disorders and X-Adrenoleukodystrophy in Dried Blood Spots by Tandem Mass Spectrometry

Journal

CLINICAL CHEMISTRY
Volume 62, Issue 9, Pages 1248-1254

Publisher

AMER ASSOC CLINICAL CHEMISTRY
DOI: 10.1373/clinchem.2016.256255

Keywords

-

Funding

  1. Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health [HHSN275201000017C]
  2. T. Denny Sanford Professorship fund
  3. Newborn Screening Translational Research Network [HHSN275200800001C 01]
  4. Mayo Clinic
  5. Legacy of Angels Foundation
  6. Glaxo Smith Kline
  7. Hunter's Hope Foundation

Ask authors/readers for more resources

BACKGROUND: Newborn screening for lysosomal storage disorders (LSD) has revealed that late-onset variants of these conditions are unexpectedly frequent and therefore may evade diagnosis. We developed an efficient and cost-effective multiplex assay to diagnose six LSDs and several peroxisomal disorders in patients presenting with diverse phenotypes at any age. METHODS: Three 3-mm dried blood spot (DBS) punches were placed into individual microtiter plates. One disc was treated with a cocktail containing acid sphingomyelinase-specific substrate and internal standard (IS). To the second DBS we added a cocktail containing substrate and IS for beta-glucosidase, acid alpha-glucosidase, alpha-galactosidase A, galactocerebrosidase, and alpha-L-iduronidase. The third DBS was extracted with methanol containing d(4)-C-26 lysophosphatidylcholine as IS and stored until the enzyme plates were combined and purified by liquid-liquid and solid-phase extraction. The extracts were evaporated, reconstituted with the extract from the lysophosphatidylcholine plate, and analyzed by flow injection tandem mass spectrometry. RESULTS: Reference intervals were determined by analysis of 550 samples from healthy controls. DBS from confirmed patients with 1 of the 6 LSDs (n = 33), X-adrenoleukodystrophy (n = 9), or a peroxisomal biogenesis disorder (n = 5), as well as carriers for Fabry disease (n = 17) and X-adrenoleukodystrophy (n = 5), were analyzed for assay validation. Prospective clinical testing of 578 samples revealed 25 patients affected with 1 of the detectable conditions. CONCLUSIONS: Our flow injection tandem mass spectrometry approach is amenable to high-throughput population screening for Hurler disease, Gaucher disease, Niemann-Pick A/B disease, Pompe disease, Krabbe disease, Fabry disease, X-adrenoleukodystrophy, and peroxisomal biogenesis disorder in DBS. (C) 2016 American Association for Clinical Chemistry

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available